Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1996 Mar;223(3):303–315. doi: 10.1097/00000658-199603000-00012

Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.

J S Solomkin 1, H H Reinhart 1, E P Dellinger 1, J M Bohnen 1, O D Rotstein 1, S B Vogel 1, H H Simms 1, C S Hill 1, H S Bjornson 1, D C Haverstock 1, H O Coulter 1, R M Echols 1
PMCID: PMC1235120  PMID: 8604912

Abstract

OBJECTIVE: In a randomized, double-blind, multicenter trial, ciprofloxacin/metronidazole was compared with imipenem/cilastatin for treatment of complicated intra-abdominal infections. A secondary objective was to demonstrate the ability to switch responding patients from intravenous (IV) to oral (PO) therapy. SUMMARY BACKGROUND DATA: Intra-abdominal infections result in substantial morbidity, mortality, and cost. Antimicrobial therapy often includes a 7- to 10-day intravenous course. The use of oral antimicrobials is a recent advance due to the availability of agents with good tissue pharmacokinetics and potent aerobic gram-negative activity. METHODS: Patients were randomized to either ciprofloxacin plus metronidazole intravenously (CIP/MTZ IV) or imipenem intravenously (IMI IV) throughout their treatment course, or ciprofloxacin plus metronidazole intravenously and treatment with oral ciprofloxacin plus metronidazole when oral feeding was resumed (CIP/MTZ IV/PO). RESULTS: Among 671 patients who constituted the intent-to-treat population, overall success rates were as follows: 82% for the group treated with CIP/MTZ IV; 84% for the CIP/MTZ IV/PO group; and 82% for the IMI IV group. For 330 valid patients, treatment success occurred in 84% of patients treated with CIP/MTZ IV, 86% of those treated with CIP/MTZ IV/PO, and 81% of the patients treated with IMI IV. Analysis of microbiology in the 30 patients undergoing intervention after treatment failure suggested that persistence of gram-negative organisms was more common in the IMI IV-treated patients who subsequently failed. Of 46 CIP/MTZ IV/PO patients (active oral arm), treatment success occurred in 96%, compared with 89% for those treated with CIP/MTZ IV and 89% for those receiving IMI IV. Patients who received intravenous/oral therapy were treated, overall, for an average of 8.6 +/- 3.6 days, with an average of 4.0 +/- 3.0 days of oral treatment. CONCLUSIONS: These results demonstrate statistical equivalence between CIP/MTZ IV and IMI IV in both the intent-to-treat and valid populations. Conversion to oral therapy with CIP/MTZ appears as effective as continued intravenous therapy in patients able to tolerate oral feedings.

Full text

PDF
303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barie P. S., Christou N. V., Dellinger E. P., Rout W. R., Stone H. H., Waymack J. P. Pathogenicity of the enterococcus in surgical infections. Ann Surg. 1990 Aug;212(2):155–159. doi: 10.1097/00000658-199008000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bauernfeind A. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother. 1993 Apr;31(4):505–522. doi: 10.1093/jac/31.4.505. [DOI] [PubMed] [Google Scholar]
  3. Beam T. R., Jr, Gilbert D. N., Kunin C. M. European guidelines for anti-infective drug products. Introduction. Clin Infect Dis. 1993 Oct;17(4):787–788. doi: 10.1093/clinids/17.4.787. [DOI] [PubMed] [Google Scholar]
  4. Beam T. R., Jr, Gilbert D. N., Kunin C. M. General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S5–32. doi: 10.1093/clind/15.supplement_1.s5. [DOI] [PubMed] [Google Scholar]
  5. Bennion R. S., Baron E. J., Thompson J. E., Jr, Downes J., Summanen P., Talan D. A., Finegold S. M. The bacteriology of gangrenous and perforated appendicitis--revisited. Ann Surg. 1990 Feb;211(2):165–171. doi: 10.1097/00000658-199002000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Berne T. V., Yellin A. E., Appleman M. D., Heseltine P. N., Gill M. A. A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis. Surg Gynecol Obstet. 1993;177 (Suppl):18–40. doi: 10.1016/0020-7292(94)90428-6. [DOI] [PubMed] [Google Scholar]
  7. Bohnen J. M., Solomkin J. S., Dellinger E. P., Bjornson H. S., Page C. P. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg. 1992 Jan;127(1):83–89. doi: 10.1001/archsurg.1992.01420010097015. [DOI] [PubMed] [Google Scholar]
  8. Bohnen J., Boulanger M., Meakins J. L., McLean A. P. Prognosis in generalized peritonitis. Relation to cause and risk factors. Arch Surg. 1983 Mar;118(3):285–290. doi: 10.1001/archsurg.1983.01390030017003. [DOI] [PubMed] [Google Scholar]
  9. Brismar B., Malmborg A. S., Tunevall G., Wretlind B., Bergman L., Mentzing L. O., Nyström P. O., Kihlström E., Bäckstrand B., Skau T. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother. 1992 Dec;36(12):2766–2773. doi: 10.1128/aac.36.12.2766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Brook I. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities. Antimicrob Agents Chemother. 1993 May;37(5):997–1000. doi: 10.1128/aac.37.5.997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dan M., Serour F., Poch F. Penetration of ciprofloxacin into human peritoneal tissue following a single oral dose of 750 milligrams. J Chemother. 1992 Feb;4(1):27–29. doi: 10.1080/1120009x.1992.11739134. [DOI] [PubMed] [Google Scholar]
  12. Dan M., Zuabi T., Quassem C., Rotmensch H. H. Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams. Antimicrob Agents Chemother. 1992 Mar;36(3):677–678. doi: 10.1128/aac.36.3.677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Davis R. L., Koup J. R., Williams-Warren J., Weber A., Smith A. L. Pharmacokinetics of three oral formulations of ciprofloxacin. Antimicrob Agents Chemother. 1985 Jul;28(1):74–77. doi: 10.1128/aac.28.1.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fink M. P., Snydman D. R., Niederman M. S., Leeper K. V., Jr, Johnson R. H., Heard S. O., Wunderink R. G., Caldwell J. W., Schentag J. J., Siami G. A. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994 Mar;38(3):547–557. doi: 10.1128/aac.38.3.547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Frost R. W., Lasseter K. C., Noe A. J., Shamblen E. C., Lettieri J. T. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):830–832. doi: 10.1128/aac.36.4.830. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gilbert D. N., Beam T. R., Jr, Kunin C. M. The path to new FDA guidelines for clinical evaluation of anti-infective drugs. Rev Infect Dis. 1991 Sep-Oct;13 (Suppl 10):S890–S894. doi: 10.1093/clinids/13.supplement_10.s890. [DOI] [PubMed] [Google Scholar]
  17. Hackford A. W., Tally F. P., Reinhold R. B., Barza M., Gorbach S. L. Prospective study comparing imipenem-cilastatin with clindamycin and gentamicin for the treatment of serious surgical infections. Arch Surg. 1988 Mar;123(3):322–326. doi: 10.1001/archsurg.1988.01400270056008. [DOI] [PubMed] [Google Scholar]
  18. Heseltine P. N., Yellin A. E., Appleman M. D., Gill M. A., Chenella F. C., Kern J. W., Berne T. V. Perforated and gangrenous appendicitis: an analysis of antibiotic failures. J Infect Dis. 1983 Aug;148(2):322–329. doi: 10.1093/infdis/148.2.322. [DOI] [PubMed] [Google Scholar]
  19. Höffken G., Lode H., Prinzing C., Borner K., Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother. 1985 Mar;27(3):375–379. doi: 10.1128/aac.27.3.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ledergerber B., Bettex J. D., Joos B., Flepp M., Lüthy R. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother. 1985 Mar;27(3):350–352. doi: 10.1128/aac.27.3.350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lennard E. S., Dellinger E. P., Wertz M. J., Minshew B. H. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg. 1982 Jan;195(1):19–24. doi: 10.1097/00000658-198201001-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lettieri J. T., Rogge M. C., Kaiser L., Echols R. M., Heller A. H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992 May;36(5):993–996. doi: 10.1128/aac.36.5.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Muller E. L., Pitt H. A., Thompson J. E., Jr, Doty J. E., Mann L. L., Manchester B. Antibiotics in infections of the biliary tract. Surg Gynecol Obstet. 1987 Oct;165(4):285–292. [PubMed] [Google Scholar]
  24. Paradis D., Vallée F., Allard S., Bisson C., Daviau N., Drapeau C., Auger F., LeBel M. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother. 1992 Oct;36(10):2085–2092. doi: 10.1128/aac.36.10.2085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Peacock J. E., Jr, Pegram P. S., Weber S. F., Leone P. A. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Am J Med. 1989 Nov 30;87(5A):185S–190S. doi: 10.1016/0002-9343(89)90055-7. [DOI] [PubMed] [Google Scholar]
  26. Polk H. C., Jr, Fink M. P., Laverdiere M., Wilson S. E., Garber G. E., Barie P. S., Hebert J. C., Cheadle W. G. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. Am Surg. 1993 Sep;59(9):598–605. [PubMed] [Google Scholar]
  27. Roberts J. P. Quantitative bacterial flora of acute appendicitis. Arch Dis Child. 1988 May;63(5):536–540. doi: 10.1136/adc.63.5.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sanders W. E., Jr Efficacy, safety, and potential economic benefits of oral ciprofloxacin in the treatment of infections. Rev Infect Dis. 1988 May-Jun;10(3):528–543. doi: 10.1093/clinids/10.3.528. [DOI] [PubMed] [Google Scholar]
  29. Sirinek K. R., Levine B. A. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet. 1991;172 (Suppl):30–35. [PubMed] [Google Scholar]
  30. Solomkin J. S., Dellinger E. P., Christou N. V., Busuttil R. W. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg. 1990 Nov;212(5):581–591. doi: 10.1097/00000658-199011000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Solomkin J. S., Dellinger E. P., Christou N. V., Mason A. D., Jr Design and conduct of antibiotic trials. A report of the Scientific Studies Committee of the Surgical Infection Society. Arch Surg. 1987 Feb;122(2):158–164. doi: 10.1001/archsurg.1987.01400140040004. [DOI] [PubMed] [Google Scholar]
  32. Solomkin J. S., Hemsell D. L., Sweet R., Tally F., Bartlett J. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992 Nov;15 (Suppl 1):S33–S42. doi: 10.1093/clind/15.supplement_1.s33. [DOI] [PubMed] [Google Scholar]
  33. Solomkin J. S., Meakins J. L., Jr, Allo M. D., Dellinger E. P., Simmons R. L. Antibiotic trials in intra-abdominal infections. A critical evaluation of study design and outcome reporting. Ann Surg. 1984 Jul;200(1):29–39. doi: 10.1097/00000658-198407000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Stratton C. Fluoroquinolone antibiotics: properties of the class and individual agents. Clin Ther. 1992 May-Jun;14(3):348–347. [PubMed] [Google Scholar]
  35. Thadepalli H., Bansal M. B., Rao B., See R., Chuah S. K., Marshall R., Dhawan V. K. Ciprofloxacin: in vitro, experimental, and clinical evaluation. Rev Infect Dis. 1988 May-Jun;10(3):505–515. doi: 10.1093/clinids/10.3.505. [DOI] [PubMed] [Google Scholar]
  36. Walker A. P., Nichols R. L., Wilson R. F., Bivens B. A., Trunkey D. D., Edmiston C. E., Jr, Smith J. W., Condon R. E. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg. 1993 Feb;217(2):115–121. doi: 10.1097/00000658-199302000-00004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Whiting J. L., Cheng N., Chow A. W. Interactions of ciprofloxacin with clindamycin, metronidazole, cefoxitin, cefotaxime, and mezlocillin against gram-positive and gram-negative anaerobic bacteria. Antimicrob Agents Chemother. 1987 Sep;31(9):1379–1382. doi: 10.1128/aac.31.9.1379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Wise R., Donovan I. A., Lockley M. R., Drumm J., Andrews J. M. The pharmacokinetics and tissue penetration of imipenem. J Antimicrob Chemother. 1986 Dec;18 (Suppl E):93–101. doi: 10.1093/jac/18.supplement_e.93. [DOI] [PubMed] [Google Scholar]
  39. Yellin A. E., Heseltine P. N., Berne T. V., Appleman M. D., Gill M. A., Riggio C. E., Chenella F. C. The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet. 1985 Oct;161(4):303–307. [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES